Tirzepatide vs Semaglutide: What SURMOUNT-5 Showed | Harbor

For years, the question of whether tirzepatide or semaglutide is the better obesity medication relied on indirect comparisons, cross-trial guesswork, and a single diabetes-focused study that used the wrong semaglutide dose for weight loss. That changed in May 2025 when the New England Journal of Medicine published the results of SURMOUNT-5, the first randomized, head-to-head trial pitting tirzepatide (Zepbound) against semaglutide (Wegovy) at their maximum approved obesity doses over 72 weeks. The results were decisive, but they weren't simple. Tirzepatide delivered roughly 47% more weight loss than semaglutide. Yet the trial's design and the broader clinical picture deserve more scrutiny than most headlines offered. Here's what the data actually says and what it doesn't.

Mechanisms of Action

Tirzepatide and semaglutide both act as incretin mimetics, but their mechanisms of action differ in important ways. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the natural GLP-1 hormone to enhance insulin secretion, suppress appetite, slow gastric emptying, and lower blood sugar. Tirzepatide, in contrast, is a dual agonist that targets both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. By activating both pathways, tirzepatide amplifies metabolic effects, improving fat metabolism, increasing insulin release, and reducing appetite more robustly than GLP-1 agonism alone. This dual mechanism underlies tirzepatide’s superior weight loss and metabolic benefits.

Compounded semaglutide being prepared as a man wearing a wedding ring holds a blue injection pen with a needle attached while seated at home

Approved Uses and Indications

Tirzepatide and semaglutide are two leading medications in the treatment of metabolic diseases, but their approved uses and indications differ in important ways. Understand the approved medical uses for tirzepatide and semaglutide, including which conditions they are indicated to treat and the specific brands involved.

Cardiovascular and Renal Indications: Ozempic (semaglutide) is FDA-approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease, and to reduce the risk of worsening kidney disease in those with chronic kidney disease. Tirzepatide does not yet carry these indications.
Recent Expansions: Zepbound (tirzepatide) recently gained approval for treating moderate to severe obstructive sleep apnea in adults with obesity. Wegovy (semaglutide) received accelerated approval for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults.
Pediatric Approvals: Wegovy (semaglutide) is approved for weight management in adolescents aged 12 and older with obesity, while Mounjaro (tirzepatide) is approved for type 2 diabetes in children 10 years and older. Neither drug is currently approved for weight management in children under 12.

While both tirzepatide and semaglutide are powerful agents for metabolic disease, their approved uses differ by condition, age group, and brand. Learn the factors that patients and healthcare providers might consider when choosing between tirzepatide and semaglutide, including individual health goals, risk factors, and preferences. Reviewing these distinctions ensures the right medication is matched to each patient’s specific clinical profile.

Why SURMOUNT-5 Matters More Than the Trial You've Probably Seen Cited

Before SURMOUNT-5, most comparisons between tirzepatide and semaglutide leaned on SURPASS-2, a 2021 trial published in the same journal. That study was rigorous, and it's now largely irrelevant for obesity comparisons. Understanding why is critical to interpreting the newer data. One must understand the findings from meta-analyses and other comparative studies beyond the SURMOUNT-5 trial to be able to provide a broader context for the efficacy and safety of both medications.

SURPASS-2 enrolled patients with type 2 diabetes, not obesity without diabetes. Its primary endpoint was blood sugar control (HbA1c), not weight loss. Most importantly, semaglutide was dosed at 1 mg weekly, which is the standard diabetes dose marketed as Ozempic. The obesity dose, 2.4 mg weekly (marketed as Wegovy), is more than double that. Comparing tirzepatide at 15 mg against semaglutide at 1 mg and declaring a winner on weight loss is like comparing a marathon runner's 5K split against a jogger's warm-up lap.

SURMOUNT-5 corrected every one of those issues. It enrolled 751 adults with obesity or overweight (BMI ≥30, or ≥27 with at least one comorbidity) who did not have type 2 diabetes. Both drugs were titrated to their maximum tolerated doses. Tirzepatide at 10 or 15 mg and semaglutide at 1.7 or 2.4 mg. The primary endpoint was the percent change in body weight at 72 weeks. The trial ran across 32 sites in the United States and Puerto Rico from April 2023 through November 2024.

The Weight Loss Numbers: 20.2% vs. 13.7%

At 72 weeks, participants on tirzepatide lost an average of 20.2% of their body weight compared with 13.7% for semaglutide. In absolute terms, that's 22.8 kg (about 50 pounds) versus 15.0 kg (about 33 pounds). The estimated treatment difference was 6.5 percentage points, with a 95% confidence interval of 4.9 to 8.1, meaning the gap between the two drugs was both statistically significant and clinically substantial.

The threshold data tells an even more revealing story. Among tirzepatide users, 81.6% achieved at least 10% weight loss, compared with 60.5% on semaglutide. At the 15% threshold, the split was 64.6% versus 40.1%. At 20%, it was 48.4% versus 27.3%. And at the 25% mark, a level of weight loss that approaches what bariatric surgery delivers, 31.6% of the tirzepatide group got there, compared with 16.1% on semaglutide. As a surrogate for visceral fat that correlates with cardiovascular and metabolic risk, waist circumference was also separated meaningfully. Areduction of 18.4 cm with tirzepatide versus 13.0 cm with semaglutide.

Why the Dual-Agonist Mechanism Makes a Pharmacological Difference

GLP-1 receptor agonists have transformed the management of type 2 diabetes and obesity by harnessing a single, powerful biological pathway. These medications mimic glucagon-like peptide-1, an incretin hormone that suppresses appetite, slows gastric emptying, and enhances insulin secretion.

Liraglutide was among the first GLP-1 receptor agonists to gain widespread clinical adoption, establishing the foundation for the entire drug class. Administered as a once-daily subcutaneous injection, it demonstrated meaningful reductions in blood glucose levels and body weight in landmark trials. Its shorter half-life requires consistent daily dosing, which some patients find demanding.
Dulaglutide advanced the GLP-1 class by offering once-weekly dosing through a pre-filled, single-use pen designed for simplicity. Its longer duration of action reduces the burden of daily injections, improving adherence for many patients managing type 2 diabetes. Clinical trials showed that dulaglutide effectively lowers hemoglobin A1c levels and supports moderate weight loss. By making treatment less intrusive, dulaglutide broadened access to GLP-1 therapy and encouraged patients who might otherwise resist injectable medications to begin treatment earlier.
Semaglutide has emerged as the most potent agent in the GLP-1 receptor agonist class, delivering superior reductions in both blood glucose and body weight compared to its predecessors. Available in once-weekly injectable and once-daily oral formulations, it offers flexibility that no other GLP-1 agonist currently matches. High-dose semaglutide has also secured regulatory approval specifically for chronic weight management.

Together, they illustrate the rapid evolution of GLP-1 receptor agonist therapy. From daily injections to weekly dosing and oral formulations, each successive agent has expanded the clinical toolkit while operating on the same fundamental mechanism.

Tirzepatide is something different. It's a dual GIP/GLP-1 receptor agonist, simultaneously activating receptors for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Research revealed that tirzepatide is actually an "imbalanced and biased" dual agonist. It binds with roughly five-fold lower affinity to the GLP-1 receptor than native GLP-1, yet still outperforms pure GLP-1 agonists. The reason appears to be that synergy with GIP receptor activation amplifies the metabolic effects of even modest GLP-1 engagement, particularly in fat metabolism and energy balance. This dual mechanism isn't just a marketing distinction. Studies in GLP-1 receptor knockout mice demonstrate that GIP-driven glucose lowering occurs independently, suggesting that tirzepatide accesses metabolic pathways that semaglutide simply cannot reach. The clinical result is consistent with what the pharmacology predicts.

What GIP Actually Does

For years, some researchers questioned whether GIP agonism would even help with weight loss, since GIP levels are paradoxically elevated in obesity. But the clinical evidence has settled the debate. GIP receptor activation appears to enhance fat oxidation, improve adipose tissue metabolism, and work synergistically with GLP-1 signaling in the brain's appetite centers. Tirzepatide's success has effectively rewritten the textbook on GIP's role in metabolic disease.

What the Trial Didn't Show: Caveats Worth Taking Seriously

The Open-Label Problem

SURMOUNT-5 was open-label, meaning both participants and investigators knew who was receiving which drug. In a trial measuring weight loss, an outcome influenced by motivation, dietary adherence, and exercise behavior, this matters. A participant who knows they're on the "stronger" drug might push harder. A clinician who knows the assignment might counsel differently. The magnitude of the observed difference (6.5 percentage points) makes it unlikely that the entire effect is explained by expectation bias, but some portion of it could be.

A double-blind design would have produced cleaner data. Eli Lilly has stated that blinding was impractical given the different titration schedules and injection devices, which is a reasonable logistical argument. However, note the limitation rather than treat the 20.2% and 13.7% figures as immutable truths.

Surrogate Endpoints, Not Hard Outcomes

Weight loss is a surrogate endpoint, as it correlates with reduced cardiovascular events, improved metabolic markers, and lower mortality, but it is not itself any of those things. SURMOUNT-5 did not track heart attacks, strokes, or deaths. The ongoing SURMOUNT-MMO trial is designed to answer those questions with hard clinical endpoints, but results are still years away.

A post-hoc analysis published in the European Heart Journal Open projected that tirzepatide's greater weight loss translated to a 2.4% absolute reduction in predicted 10-year cardiovascular risk, compared with 1.4% for semaglutide. Extrapolated to the roughly 85 million eligible U.S. adults, that gap could represent 850,000 additional prevented cardiovascular events over a decade. But projections from post-hoc analyses are hypothesis-generating rather than conclusive.

Attrition and Demographics

About 15% of participants didn't complete the trial, a rate that's typical for 72-week obesity studies but still introduces uncertainty. The study population was 64.7% female with a mean age of 44.7 and a higher-than-usual male representation (35%), which may partly explain why overall weight loss was somewhat lower than in prior tirzepatide-only trials.

Body Composition: The Under-Discussed Dimension

The composition of that weight loss, how much is fat versus lean tissue, has significant implications for metabolic health, physical function, and long-term outcomes. Data from the SURMOUNT-1 and STEP-1 trials offer the best available comparison. In STEP-1, semaglutide produced a total weight reduction of 15.3 kg, of which 6.92 kg (about 45%) came from lean mass. In SURMOUNT-1, tirzepatide at its highest dose produced a larger total reduction of 22.1 kg, but only 5.67 kg (about 26%) came from lean mass. Tirzepatide induced substantially more total weight loss while preserving a greater proportion of lean tissue.

GLP-1 drugs for weight loss including two injectable pen syringes with needle tips displayed alongside a stethoscope on a beige background

The ratio matters because lean mass drives resting metabolic rate, supports physical independence, and is associated with better cardiometabolic outcomes. A weight-loss intervention that strips away muscle alongside fat is less valuable than one that preferentially targets fat stores. By this measure, tirzepatide's body composition profile appears favorable, with roughly 75% of the weight loss coming from fat mass, compared with about 61% for semaglutide.

Imaging data from the SURPASS-3 MRI sub-study added another layer. Tirzepatide appeared to reduce fat infiltration within muscle tissue, potentially improving muscle quality even as total lean mass declined. This is an emerging area of research, and the data remains preliminary. But it suggests that the standard weight-on-a-scale metric may understate tirzepatide's metabolic advantages. None of this means muscle loss is irrelevant. Both drugs cause some lean tissue reduction, and resistance training combined with adequate protein intake is strongly recommended during treatment with either medication.

The Cardiovascular Question: Different Trials, Different Answers

For many patients and clinicians, the most consequential question is which drug reduces heart attacks and strokes. Here, the picture is more nuanced than the weight data. Semaglutide has the strongest direct evidence. The SELECT trial, a placebo-controlled study of over 17,600 participants with established cardiovascular disease, demonstrated a 20% reduction in major adverse cardiovascular events (MACE) over a mean follow-up of nearly 40 months. This is a landmark result, and it's the reason Wegovy carries an FDA-approved indication for cardiovascular risk reduction in patients with established heart disease and overweight or obesity. No other incretin-based obesity therapy has this indication.

Tirzepatide's cardiovascular story is less direct. The SURPASS-CVOT trial compared tirzepatide against dulaglutide (Trulicity), an active GLP-1 comparator, in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Over a median of four years, tirzepatide was noninferior to dulaglutide on the primary MACE endpoint but did not achieve superiority.

The critical design difference: SELECT compared semaglutide against placebo, while SURPASS-CVOT compared tirzepatide against an already-effective active comparator. Beating placebo by 20% is a different accomplishment than matching or modestly exceeding dulaglutide. Cross-trial comparisons between these two studies are methodologically fraught.

The most informative real-world data came in late 2025, when a study published in Nature Medicine analyzed cardiovascular outcomes across five large U.S. insurance cohorts comparing tirzepatide and semaglutide directly. The head-to-head hazard ratio for major cardiovascular events was 1.06 (95% CI 0.95–1.18), which is essentially identical.

For patients with established cardiovascular disease, semaglutide currently has the strongest evidence base and the specific FDA indication. For patients whose primary concern is weight reduction and metabolic improvement without prior cardiovascular events, the picture is less clear-cut, and the SURMOUNT-MMO trial may eventually shift the balance.

Side Effects: Similar Profiles, Different Discontinuation Rates

Gastrointestinal side effects are the most common tolerability concern with both tirzepatide and semaglutide, particularly during dose escalation. While overall adverse event rates are similar, differences in severity and discontinuation suggest meaningful variation in how patients experience these symptoms. Below is a breakdown of the four primary GI side effects:

Nausea: This is the most commonly reported gastrointestinal complaint and typically emerges during dose increases or within the first several months of therapy. It is thought to result from delayed gastric emptying and central appetite signaling effects. Most cases are mild to moderate and improve over time as the body adapts. However, persistent nausea can interfere with hydration, nutrition, and quality of life.
Vomiting: Episodes are usually clustered early in treatment and often correlate with rapid titration or higher doses. Repeated vomiting can increase the risk of dehydration, electrolyte imbalance, and temporary treatment interruption. Although most cases resolve with dose adjustments or slower escalation, severe vomiting contributes disproportionately to discontinuation decisions. Its presence may signal that a patient requires closer monitoring or a modified dosing strategy to improve tolerability.
Diarrhea: It may stem from altered gut motility and hormonal signaling changes within the gastrointestinal tract. While often self-limited, ongoing diarrhea can lead to fluid loss, fatigue, and reduced medication adherence. For some patients, frequency and urgency affect daily routines and work performance. Gradual titration and dietary adjustments may help mitigate symptoms, but persistent cases can still influence a patient’s willingness to continue therapy.
Constipation: It may develop gradually and become more noticeable after several weeks of therapy. Though typically mild, untreated constipation can cause bloating, abdominal discomfort, and straining. In rare cases, prolonged symptoms may require pharmacologic management. Patients with preexisting motility disorders may be more susceptible. While constipation alone is less likely to drive discontinuation, cumulative GI discomfort from multiple symptoms can affect overall treatment satisfaction and persistence.

Both medications share similar gastrointestinal side effect profiles, with most symptoms emerging early and improving over time. However, differences in discontinuation rates suggest tolerability nuances that may influence real-world adherence. Given that sustained therapy is critical for maintaining weight loss and metabolic benefits, even modest variations in GI tolerability can have meaningful long-term implications for patient outcomes.

Access, Cost, and the Insurance Landscape in 2026

Even the most effective medication is irrelevant if patients can't afford it or access it. And the insurance landscape for GLP-1 and dual-agonist obesity drugs has deteriorated significantly since these trials began. The number of commercially insured individuals with no coverage for Wegovy increased 42% from 2025 to 2026, leaving over 41 million people without access. For Zepbound, the number without coverage rose 12%, leaving over 109 million without commercial coverage. Among those who do have coverage, more than 88% face prior authorization requirements. These are the cost differences and factors affecting access to tirzepatide and semaglutide.

A major inflection point came in mid-2025, when CVS Caremark removed Zepbound from its standard formulary in favor of Wegovy. This single decision reshaped the access landscape, making semaglutide the default choice for a significant portion of the commercially insured population, regardless of clinical preference. Medicare remains largely unavailable for weight-loss indications. Wegovy may be covered when prescribed specifically for cardiovascular risk reduction in patients with established heart disease. Zepbound may be covered for obstructive sleep apnea in adults with obesity under narrow criteria.

Out-of-pocket, both drugs have become more accessible. Eli Lilly offers Zepbound starting at $299 per month for patients paying cash, with $25 copay cards for those with qualifying commercial insurance. Wegovy is available through NovoCare Pharmacy at $199 per month for new users, with ongoing fills at $299 to $349.

Making Sense of the Evidence: What This Means in Practice

SURMOUNT-5 established tirzepatide as the more effective weight-loss medication by a meaningful margin. The 6.5-percentage-point advantage over semaglutide is clinically significant, pharmacologically explainable, and consistent with real-world observational data. Tirzepatide also appears to preserve lean mass more effectively and has a lower rate of GI-related treatment discontinuation.

But "more effective at weight loss" is not the same as "better for every patient." Semaglutide retains important advantages with proven cardiovascular event reduction in the SELECT trial, broader insurance coverage following the CVS Caremark shift, an FDA-approved oral formulation (Rybelsus), and approval for adolescents aged 12 and older with obesity.

The honest framework for choosing between them involves layering several questions. What is the patient's primary clinical goal: maximum weight reduction, cardiovascular risk management, or glycemic control? What does their insurance cover? How do they tolerate GI side effects? Do they have established cardiovascular disease? Are hard cardiovascular outcome data essential to the decision, or is the weight-loss and metabolic improvement evidence sufficient? Explore personalized weight-loss & metabolic care options by visiting Harbor and connecting with a licensed clinician today.

Semaglutide for weight loss administered via a blue injection pen being prepared with a needle tip beside its white medical packaging on a wooden surface

Neither drug is wrong for obesity treatment. Both produce clinically meaningful weight loss that exceeds anything available a decade ago. But they are not interchangeable, and SURMOUNT-5 provided clinicians and patients with the clearest evidence yet on exactly how they differ. SURMOUNT-MMO's hard cardiovascular endpoints for tirzepatide, the CMS BALANCE Medicare demonstration, and inevitable next-generation triple agonists already in late-stage trials will continue to reshape this landscape. For now, the data from SURMOUNT-5 are the best compass we have, and they point clearly: for weight loss in adults with obesity, tirzepatide outperforms semaglutide by a substantial and reproducible margin.

Tirzepatide vs. Semaglutide: What the Head-to-Head SURMOUNT-5 Trial Actually Showed